Victory Capital Management Inc Aldeyra Therapeutics, Inc. Transaction History

Victory Capital Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 06, 2023	SELL	$6.11 - $8.16 $870,797 - $1.16 Million	-142,520 Reduced 78.11%	39,930 $266,000
Q2 2023 Jul 27, 2023	BUY	$7.11 - $11.89 $314,048 - $525,181	44,170 Added 31.94%	182,450 $1.53 Million
Q1 2023 May 02, 2023	SELL	$5.77 - $9.93 $207,777 - $357,579	-36,010 Reduced 20.66%	138,280 $1.37 Million
Q4 2022 Feb 09, 2023	BUY	$5.08 - $7.09 $543,052 - $757,921	106,900 Added 158.63%	174,290 $1.21 Million
Q3 2022 Nov 02, 2022	BUY	$3.8 - $7.74 $256,082 - $521,598	67,390 New	67,390 $360,000
Q2 2020 Aug 07, 2020	SELL	$1.97 - $5.05 $7,344 - $18,826	-3,728 Closed	0 $0
Q1 2020 May 04, 2020	SELL	$1.62 - $6.4 $137 - $544	-85 Reduced 2.23%	3,728 $9,000
Q4 2019 Feb 04, 2020	SELL	$4.73 - $7.98 $2,100 - $3,543	-444 Reduced 10.43%	3,813 $20,000
Q3 2019 Nov 12, 2019	BUY	$4.41 - $6.12 $18,773 - $26,052	4,257 New	4,257 $22,000

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $279M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.